|
|
|
| folic acid，squamous cell carcinoma associated antigen and carbohydrate antigen 125 in patients with locally advanced cervical cancer |
| GAO Xian-qiong |
| Department of Inpatient in Western Pharmacy with Drug and Equipment,Egang Hospital,Hubei Province,Ezhou 436000,China |
|
|
|
|
Abstract Objective To investigate the effect of Irinotecan combined with Cisplatin neoadjuvant chemotherapy on serum levels of folic acid,squamous cell carcinoma associated antigen (SCC-AG) and carbohydrate antigen 125 (CA125)in patients with locally advanced cervical cancer.Methods A total of 110 patients with locally advanced cervical cancer who were admitted to Egang Hospital from January 2016 to January 2019 were selected as the research subjects.According to the treatment method,they were divided into control group (55 cases) and observation group (55 cases).The control group was treated with concurrent chemoradiotherapy before total uterine resection,and the observation group was treated with Irinotecan combined with Cisplatin neoadjuvant chemotherapy before total uterine resection.The total effective rate of treatment,the total incidence of adverse reactions and serum folic acid,SCC-Ag and CA125 levels before and after treatment were compared between the two groups.Results The total effective rate in the observation group was higher than that in the control group,and the difference was statistically significant (P＜0.05).After treatment,the serum folate level in the observation group was higher than that before treatment,and the serum folate level in the observation group was higher than that in the control group,the differences were statistically significant (P＜0.05).After treatment,the levels of SCC-Ag and CA125 in the observation group were lower than those before treatment,and the levels of SCC-Ag and CA125 in the observation group were lower than those in the control group,the differences were statistically significant (P＜0.05).There was no significant difference in the total incidence of adverse drug reactions between the two groups (P＞0.05).Conclusion The treatment of Irinotecan combined with Cisplatin neoadjuvant chemotherapy is more effective than concurrent chemoradiotherapy in the treatment of with patients locally advanced cervical cancer.It can significantly reduce the levels of SCC-Ag and CA125,increase serum levels of folic acid,without increasing the incidence of adverse drug reactions.
|
|
|
|
|
|
| [2] |
刘瑞敏.伊立替康联合奈达铂方案新辅助化疗用于局部晚期宫颈癌患者的临床疗效观察[J].肿瘤基础与临床，2017，30（2）：137-139.
|
| [1] |
Khanna V，Karjodkar F，Robbins S，et al.Estimation of serum ferritin level in potentially malignant disorders，oral squamous cell carcinoma，and treated cases of oral squamous cell carcinoma[J].J Cancer Res Ther，2017，13（3）：550-555.
|
| [3] |
黄倩羽，潘毅贞.伊立替康联合顺铂与紫杉醇联合顺铂治疗宫颈癌的临床效果观察[J].中国现代药物应用，2017，11（12）：110-111.
|
| [4] |
Pinn-Bingham M，Puthawala AA，Syed AMN，et al.Outcomes of highdose-rate interstitial brachytherapy in the treatment of locally advanced cervical cancer：Long-term results[J].Int J Radiat Oncol，2013，85（2）：714-720.
|
| [5] |
赵肖丽，王华.伊立替康联合顺铂新辅助化疗对局部晚期宫颈癌患者生活质量影响[J].山西医药杂志，2018，47（4）：367-369.
|
| [6] |
赵肖丽，周伟慢，王辉，等.伊立替康与同步放化疗对改善中晚期宫颈癌患者生活质量的临床对比研究[J].中国性科学，2018，27（7）：39-42.
|
| [7] |
李东方，肖凤仪，李波，等.伊立替康联合卡铂辅助化疗对宫颈癌患者血清叶酸和CA125水平的影响[J].河北医学，2017，23（5）：79-793.
|
| [8] |
王新会，陈欢欢，李娟，等.伊立替康联合顺铂新辅助化疗对宫颈癌患者血清CD105、OPN、SCCAg、CEA 及免 疫T细胞亚群的影响[J].海南医学院学报，2017，23（6）：797-800.
|
| [9] |
伍立群，李波，肖凤仪，等.伊立替康联合卡铂辅助化疗对宫颈癌患者血清叶酸、SCC-Ag 水平及临床疗效的影响[J].标记免疫分析与临床，2017，24（6）：676-678，716.
|
| [10] |
王婉，胡倩倩，张伟，等.伊立替康联合顺铂与紫杉醇联合顺铂治疗宫颈癌的临床疗效分析[J].中国妇幼健康研究，2017，28（1）：84-87.
|
| [11] |
张莹，刘淑杰，马天好，等.SCC-Ag 与宫颈癌新辅助化疗患者预后的相关性[J].现代肿瘤医学，2017，25（12）：1964-1967.
|
| [12] |
Denny L，Adewole I，Anorlu R，et al.Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa[J].Int J Cancer，2014，134（6）：1389-1398.
|
| [13] |
李婷，周玉冰.盐酸伊立替康联合顺铂方案治疗宫颈癌的疗效分析[J].肿瘤基础与临床，2017，30（6）：480-482.
|
| [14] |
王金华，郑秀，陈丽红，等.血清鳞癌相关抗原、糖类抗原125 表达与宫颈癌临床分期的相关性[J].中国临床药理学杂志，2015，31（15）：1546-1548.
|
| [15] |
王华，王辉，赵肖丽.伊立替康同步放化疗对中晚期宫颈癌患者的疗效及SF-36、SSRS评分的影响[J].中国妇幼保健，2018，33（24）：5746-5748.
|
|
|
|
